Macular Degeneration: Gomi F

Gomi F. · No affiliation provided · Nippon Ganka Gakkai Zasshi. · Pubmed #17025222 No free full text.

This publication has no abstract.

Gomi F, Tano Y. · Department of Ophthalmology, Osaka University Medical School, Osaka, Japan. · Curr Opin Ophthalmol. · Pubmed #18408495 No free full text.

Abstract: PURPOSE OF REVIEW: This review assesses the current knowledge of the clinical characteristics of polypoidal choroidal vasculopathy and treatments. RECENT FINDINGS: Polypoidal choroidal vasculopathy is a disease with characteristic choroidal vascular abnormalities. Indocyanine green angiography is essential for diagnosis. The prevalence is higher in Asian people than in Caucasians. Photodynamic therapy is efficacious for treating polypoidal choroidal vasculopathy; 1-year results have shown greater benefit of photodynamic therapy than choroidal neovascularization secondary to age-related macular degeneration. Recurrence, however, seriously affects vision long term during follow-up after photodynamic therapy. The lower efficacy of bevacizumab- a full-length antibody of vascular endothelial growth factor- has been shown for polypoidal choroidal vasculopathy. SUMMARY: Although the polypoidal choroidal vasculopathy and age-related macular degeneration have been known to share common genetic factors, its clinical characteristics including the different responses to photodynamic therapy suggest that polypoidal choroidal vasculopathy is a separate clinical entity from age-related macular degeneration. The results of photodynamic therapy for polypoidal choroidal vasculopathy are encouraging; however, recurrence may affect vision over time. Therapeutic modalities to inhibit development of the exudative choroidal vasculature of polypoidal choroidal vasculopathy are desirable.

Shima C, Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Tano Y. · Department of Ophthalmology, Osaka University Medical School, Suita, Osaka, Japan. · Graefes Arch Clin Exp Ophthalmol. · Pubmed #19308441 No free full text.

Abstract: BACKGROUND: To evaluate the efficacy of combined photodynamic therapy (PDT) and intravitreal bevacizumab injection in eyes with a serous pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD). METHODS: Twenty-two eyes with a serous PED exceeding two disc areas associated with AMD with choroidal vascular abnormalities [choroidal neovascularization (n = 10), polypoidal choroidal vasculopathy (n = 9), and retinal angiomatous proliferation (n = 3)] received combined PDT and intravitreal bevacizumab, and were followed about every 6 weeks for more than 1 year. Additional treatments were given for residual or recurrent lesions. The main outcome measures were changes in the PED height measured by optical coherence tomography, and the best-corrected visual acuity. RESULTS: After one treatment, the PED resolved in 12 eyes (55%) and the PED decreased in ten eyes (45%). There was no recurrence in eight (36%) eyes; however, PED recurred in 14 eyes. At 1 year, the average PED height decreased to 413 microns from the baseline 751 microns (p < 0.001). Twenty eyes (91%) had improved or stabilized vision; two eyes had decreased vision due to a retinal pigment epithelial tear and subretinal hemorrhage. CONCLUSIONS: Combined PDT and intravitreal bevacizumab may decrease the PED height and stabilize visual acuity at 1 year.

Bessho K, Gomi F, Harino S, Sawa M, Sayanagi K, Tsujikawa M, Tano Y. · Department of Ophthalmology, Osaka University Medical School, Suita, Osaka, Japan. · Graefes Arch Clin Exp Ophthalmol. · Pubmed #19184082 No free full text.

Abstract: BACKGROUND: Fundus autofluorescence (AF) derives from lipofuscin in the retinal pigment epithelium (RPE). Because lipofuscin is a by-product of phagocytosis of photoreceptors by RPE, AF imaging is expected to describe some functional aspect of the retina. In this study we report distribution of AF in patients showing macular edema. METHODS: Three eyes with diabetic macular edema (DME) and 11 with retinal vein occlusion (RVO), associated with macular edema (ME) were examined. ME was determined by standard fundus examination, fluorescein angiography (FA) and optical coherence tomography (OCT). AF was recorded using a Heidelberg confocal scanning laser ophthalmoscope (cSLO) with 488 nm laser exciter (488 nm-AF), and a conventional Topcon fundus camera with halogen lamp exciter and 580 nm band-pass filter (580 nm-AF). Color fundus picture, FA image and these two AF images were analyzed by superimposing all images. RESULTS: All subjects presented cystoid macular edema (CME) with petaloid pattern hyperfluorescence in FA. In 488 nm-AF, all eyes (100%) showed macular autofluorescence of a similar shape to that of the CME in FA. In contrast, in 580 nm-AF only one eye (7%) presented this corresponding petaloid-shaped autofluorescence. In all cases, peripheral retinal edemas did not show autofluorescence corresponding to the leakage in FA. CONCLUSIONS: In eyes with CME, analogous hyperautofluorescence to the CME was always observed in 488 nm-AF, while it was rarely observed in 580 nm-AF. Moreover, this CME hyperautofluorescence was only seen in the macular area. We hypothesize that autofluorescence from CME may be considered as a "pseudo" or "relative" autofluorescence, due to macular stretching following CME that may result in lateral displacement of macular pigments (MPs) and subsequent reduction of MPs density, as MPs block 488 nm-AF more intensely than 580 nm-AF. Although this phenomenon may not directly indicate change of RPE function, it may be used as a method to assess or track CME non-invasively.

Fang X, Sakaguchi H, Gomi F, Oshima Y, Sawa M, Tsujikawa M, Ikuno Y, Kamei M, Kusaka S, Tano Y. · Department of Ophthalmology, Osaka University Medical School, Osaka, Japan. · Acta Ophthalmol. · Pubmed #18547274 No free full text.

Abstract: PURPOSE: To assess the efficacy, duration of effect and safety of one intravitreal injection of bevacizumab in diabetic macular oedema (DMO). METHODS: Bevacizumab (1 mg/0.04 ml) was injected intravitreally into eyes with DMO (29 with and nine without previous treatments). Best corrected visual acuity (BCVA), intraocular pressure and central retinal thickness (CRT) were measured; slit-lamp examination, macular biomicroscopy, optical coherence tomography and fluorescein angiography were performed before and at 2-4, 8 and 12 weeks post-injection. Best corrected VA and CRT were analysed in both groups. RESULTS: In the non-pretreated group, mean BCVA improved from 0.76 +/- 0.33 (baseline) to 0.57 +/- 0.30 and 0.54 +/- 0.27 at 2-4 weeks and 8 weeks post-injection, respectively (p = 0.02, p = 0.014, paired t-test). Mean CRT decreased from 632.4 +/- 196.0 microm (baseline) to 392.3 +/- 113.6 microm and 370.4 +/- 141.7 microm at the same time-points, respectively (p = 0.01, p = 0.01). There was no difference in BCVA or CRT at 12 weeks. In the pretreated group, mean BCVA improved from 0.62 +/- 0.30 (baseline) to 0.53 +/- 0.33 at 2-4 weeks post-injection (p = 0.01), and mean CRT decreased from 583.9 +/- 180.7 microm (baseline) to 404.1 +/- 197.9 microm at 2-4 weeks post-injection (p < 0.001). Mean BCVA was unchanged at 8 weeks and 12 weeks post-injection, although mean CRT remained lower at 8 weeks (p = 0.004). No ocular or systemic side-effects developed during follow-up. CONCLUSIONS: One intravitreal injection of bevacizumab for DMO seems to be effective and safe in both eyes that have been treated previously and eyes that have not. The therapeutic effect is temporary and repeat treatment may be needed.

Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y. · Department of Ophthalmology, Osaka University Medical School, Suita, Japan. · Acta Ophthalmol. · Pubmed #18028234 No free full text.

Abstract: PURPOSE: To report complications in patients after intravitreal injection of bevacizumab to treat ocular diseases associated with vascular endothelial growth factor. METHODS: We retrospectively reviewed the systemic and ocular complications that developed within 2 months of each intravitreal injection of bevacizumab in 707 patients (1300 injections) with intraocular neovascularization or macular oedema. RESULTS: Nine ocular (1.27%) and eight systemic (1.13%) complications occurred in 707 patients. The ocular complications included corneal abrasion (n = 2), chemosis (n = 2), lens injury (n = 1), ocular inflammation (n = 2), retinal pigment epithelial tear (n = 1) and acute vision loss (n = 1). The systemic complications included cerebral infarction (n = 1), elevation of systolic blood pressure (n = 2), facial skin redness (n = 1), itchy diffuse rash (n = 1) and menstrual irregularities (n = 3). CONCLUSION: Intravitreal injection of bevacizumab may cause systemic or ocular complications. Caution is advised when considering intravitreal injection of this drug.

Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y. · Department of Ophthalmology, Osaka University Medical School, Suita, Osaka, Japan. · Ophthalmology. · Pubmed #17582498 No free full text.

Abstract: PURPOSE: To determine the prevalence of polypoidal choroidal vasculopathy (PCV) in Japanese patients presumed to have age-related macular degeneration (AMD) and compare 1-year outcomes after photodynamic therapy between PCV and choroidal neovascularization secondary to AMD. DESIGN: Prospective interventional study. PARTICIPANTS: Ninety-three consecutive patients (93 eyes) met the inclusion criteria: at least 50 years old, best-corrected visual acuity (VA) of 34 to 73 on the Early Treatment Diabetic Retinopathy Study (ETDRS) letter chart, a subfoveal lesion 5400 mum or smaller in greatest linear dimension (GLD) on fluorescein angiography (FA), and eligibility for photodynamic therapy. METHODS: Indocyanine green angiography was performed in all participants, and PCV and AMD were differentiated, treated with photodynamic therapy, and the patients observed for 1 year. The GLD was determined by FA for AMD and by indocyanine green angiography for PCV, and the diameter of the laser spot size was chosen, with an extra 1000 microm added to the GLD. Photodynamic therapy was repeated if leakage occurred on FA at 3-month follow-up visits. MAIN OUTCOME MEASURES: Prevalence of PCV at baseline and visual and angiographic changes 1 year after photodynamic therapy in PCV and AMD. RESULTS: Using indocyanine green angiography, 36 eyes (39%) were diagnosed with PCV and 54 eyes (58%) with choroidal neovascularization secondary to AMD. The median change in VA using the ETDRS letter score from baseline to 1 year was -7.0 in AMD eyes and +8.0 in PCV eyes (Mann-Whitney rank sum test; P<0.001). The VA improved (> or =15 letters) in AMD and PCV by 6% and 25%, respectively, and decreased (> or =15 letters) by 31% and 8%, respectively. Fluorescein leakage stopped at 1 year in 86% of PCV and 61% of AMD eyes (P = 0.031). Polypoidal choroidal vasculopathy recurred in 2 PCV eyes (5.6%), and a new PCV lesion developed in 1 PCV eye (2.8%) and 2 AMD eyes (3.7%) on indocyanine green angiography at 1 year. CONCLUSION: The prevalence of PCV meeting the treatment criteria for photodynamic therapy for presumed AMD is high in Japanese patients. Photodynamic therapy is more efficacious for PCV than for AMD, which may explain the good results in Japanese patients. Further study should assess the long-term clinical results.

Sayanagi K, Gomi F, Sawa M, Ohji M, Tano Y. · Department of Ophthalmology, Osaka University Medical School, Room E7, 2-2 Yamadaoka, 565-0871 Suita, Japan. · Graefes Arch Clin Exp Ophthalmol. · Pubmed #17437122 No free full text.

Abstract: PURPOSE: To report on the clinical features of three cases of polypoidal choroidal vasculopathy (PCV) during long-term follow-up after photodynamic therapy (PDT). DESIGN: Interventional case reports. METHODS: Among the participants in the Japanese Age-Related Macular Degeneration Trial (JAT) at our hospital, a PCV was seen in three eyes at baseline on retrospective analysis of indocyanine green angiography (ICGA) using fundus camera. We report the clinical features of these cases during more than 4 years follow-up. RESULTS: The mean number of PDT treatments was 5.7. Improved visual acuity (VA) and cessation of fluorescein leakage was achieved within 18 months in all eyes; however, subretinal hemorrhage and subfoveal fluid recurred due to new or recurrent PCV. The final VA decreased markedly in two eyes. CONCLUSIONS: The eyes with PCV, which had been treated successfully with PDT, may have developed new or recurrent PCV during long-term follow-up. Periodical ICGA would be needed to detect abnormal choroidal vascular changes.

Kim A, Gomi F, Sakaguchi H, Oshima Y, Ikuno Y, Kamei M, Oji M, Tano Y. · Department of Ophthalmology, Osaka University Hospital, Suita, Japan. · Nippon Ganka Gakkai Zasshi. · Pubmed #16491869 No free full text.

Abstract: PURPOSE: To evaluate the efficacy of sub-Tenon's injection of triamcinolone acetonide for age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). METHOD: Sub-Tenon's injection of triamcinolone acetonide was performed in patients (27 eyes) with the subfoveal choroidal neovascularization of AMD and in patients (10 eyes) with PCV, and its efficacy was evaluated. The visual acuity and the exudation from lesions evaluated by fluorescein angiography or optical coherence tomography (OCT) at three months or six months after injection were compared to the baseline values. RESULTS: Visual acuity was maintained in 23 of the 27 eyes (85.0%) with AMD and in 8 of the 10 eyes (80.0%) with PCV at three months after injection. Six months after infusion, the rate declined to 76.0% and 66.7%, respectively. Exudation from lesions had decreased in 10 eyes of 25 eyes(40.0%) with AMD and in 2 eyes of 9 eyes (22.2%) with PCV by six months after injection. Complete suppression of the lesions was observed in seven eyes (18.9%) with relatively small lesions. CONCLUSION: Sub-Tenon's injection of triamcinolone acetonide is useful as a treatment modality for AMD and PCV.

Cekiç O, Ohji M, KesercI B, Sawa M, Zheng Y, Hayashi A, Ikuno Y, Nakata K, Gomi F, Tano Y. · Department of Ophthalmology, Osaka University Medical School, Osaka, Japan. · Retina. · Pubmed #15097879 No free full text.

Abstract: PURPOSE: To evaluate the possible long-term alterations of choroidal perfusion parameters in the new central macular area after macular translocation surgery. METHODS: Eleven subjects with subfoveal neovascular membrane secondary to age-related macular degeneration or degenerative myopia underwent indocyanine green angiography by using a scanning laser ophthalmoscope before and after macular translocation (mean, 10 months after surgery). Fluorescence intensity of the new central macular area over time was evaluated. Parameters derived from the intensity curves included 10% filling time, ascending slope, and maximal intensity of brightness. The 10% filling time reflects the rapidity of the early choroidal filling phase, whereas the slope of the filling of the curve shows the speed of blood entrance into the choroid. Maximal intensity of brightness indicates vascular density of the area. RESULTS: No statistical difference was encountered before or after macular translocation in 10% filling time (14.25 +/- 2.09 seconds versus 16.20 +/- 2.95 seconds), slope of the ascending portion of the curve (0.12 +/- 0.04 versus 0.11 +/- 0.04), and maximal intensity of brightness (0.89 +/- 0.09 versus 0.88 +/- 0.07) in the new central macular area. The rotational degree of the retina against the retinal pigment epithelium did not show any significant correlation with 10% filling time, slope, or maximal intensity of brightness. CONCLUSION: Choroidal perfusion parameters in the new foveal region do not change after macular translocation surgery.

Cekiç O, Keserci B, Ohji M, Sawa M, Ikuno Y, Gomi F, Hayashi A, Fujikado T, Tano Y. · Department of Ophthalmology, Osaka University Medical School, E7, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. · Retina. · Pubmed #15076944 No free full text.

Abstract: PURPOSE: To quantify and compare the retinal circulation times before and after macular translocation surgery. METHODS: In nine patients undergoing macular translocation with 360-degree retinotomy, arm-retina and arteriovenous passage times were quantified from preoperative and postoperative scanning laser fluorescein angiograms. A control group of eight patients who had not undergone any intraocular surgery was also evaluated. The time that between injection into the antecubital vein and the appearance of fluorescein at two selected points on superotemporal and inferotemporal arteries near the disk provided the arm-retina time. For the arteriovenous passage time, 50% of the maximal fluorescence time difference was assessed from the intensity curves of arteries and corresponding veins at the same points for the arm-retina time. Postoperative measurements were obtained an average of 10.6 months after surgery. RESULTS: No significant difference was noted between preoperative and postoperative values of the arm-retina time (mean +/- SD: 14.41 +/- 2.73 seconds versus 14.67 +/- 3.85 seconds, respectively; P = 0.84) or that of the arteriovenous passage time (2.66 +/- 0.74 seconds versus 2.47 +/- 0.68 seconds, respectively; P = 0.37) in the study group. The arm-retina time (14.96 +/- 2.01 seconds) and arteriovenous passage time (2.44 +/- 0.68 seconds) in the control group did not differ from preoperative and postoperative arm-retina times (P = 0.65 and P = 0.85) and arteriovenous passage times (P = 0.54 and P = 0.93) in the study group. The arteriovenous passage time correlated with the degree of retinal rotation around the optic disk in the study group (r = -0.70; P = 0.04). CONCLUSION: Macular translocation surgery does not alter retinal macrocirculation in the long term.

Fukushima Y, Gomi F, Ohji M, Tano Y. · No affiliation provided · Jpn J Ophthalmol. · Pubmed #17660996 No free full text.

This publication has no abstract.